CALL/VERTEX PHARMACEUTICALS/600/0.1/17.01.25 | Real-time BOERSE MUENCHEN 09:26:25 04/06/2024 BST | ||
| 0.8 EUR | +17.82% |
|
| Current month | +34.99% | ||
| 1 month | +139.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 0.8 | +17.82% |
| 03/06/24 | 0.679 | +34.99% |
| 31/05/24 | 0.503 | +0.80% |
| 30/05/24 | 0.499 | +4.39% |
| 29/05/24 | 0.478 | -7.00% |
Real-time BOERSE MUENCHEN
Last update June 04, 2024 at 09:26 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP93AG |
| ISIN | DE000GP93AG2 |
| Date issued | 17/07/2023 |
| Strike | 600 $ |
| Maturity | 17/01/2025 (228 Days) |
| Parity | 10 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.3 € |
| Spread % | 27.52% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.2
USD
Average target price
463.5
USD
Spread / Average Target
-1.41%
- Stock Market
- Warrants
- Warrant